Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-07-18
2006-07-18
Riley, Jezia (Department: 1637)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S422000, C514S444000, C514S141000, C514S232800, C549S059000, C544S141000
Reexamination Certificate
active
07078536
ABSTRACT:
Charged compounds are provided that comprise one or more regions of localized positive charge, compositions comprising such compounds, methods of synthesizing such compounds, methods of screening such compounds to identify those having anti-infective activity, and methods of using such compounds to prevent or inhibit infections. These compounds, and compositions containing them, have multiple applications, including use in human and animal medicine and in agriculture.
REFERENCES:
patent: 4738980 (1988-04-01), Arcamone et al.
patent: 4766142 (1988-08-01), Arcamone et al.
patent: 4912199 (1990-03-01), Lown et al.
patent: 5017599 (1991-05-01), Lazzari et al.
patent: 5049579 (1991-09-01), Lazzari et al.
patent: 5310752 (1994-05-01), Lazzari et al.
patent: 5472976 (1995-12-01), Animati et al.
patent: 5502068 (1996-03-01), Lown et al.
patent: 5616606 (1997-04-01), Lown et al.
patent: 5670534 (1997-09-01), Animati et al.
patent: 5698674 (1997-12-01), Bruice et al.
patent: 5753629 (1998-05-01), Beria et al.
patent: 5801155 (1998-09-01), Kutyavin et al.
patent: 5852011 (1998-12-01), Matsunaga et al.
patent: 6090947 (2000-07-01), Dervan et al.
patent: 6555693 (2003-04-01), Ge et al.
patent: 2310207 (1996-02-01), None
patent: WO 92/13838 (1992-08-01), None
patent: WO 93/13739 (1993-07-01), None
patent: WO 94/20463 (1994-09-01), None
patent: 98/50582 (1997-07-01), None
patent: WO 98/37066 (1998-08-01), None
patent: WO 98/37067 (1998-08-01), None
patent: WO 98/37087 (1998-08-01), None
patent: WO 98/45284 (1998-10-01), None
patent: WO 98/49142 (1998-11-01), None
patent: WO 98/52614 (1998-11-01), None
patent: WO 99/27939 (1999-06-01), None
patent: WO 99/41367 (1999-08-01), None
patent: WO 99/50265 (1999-10-01), None
patent: 99/62890 (1999-12-01), None
patent: WO 99/64413 (1999-12-01), None
patent: WO 00/40605 (2000-07-01), None
Ae NimPae et al., “Synthesis and In Vitro Activity of New Oxazolidinone Antibacterial Agents Having Substituted Isoxazoles”,Bioorganic&Medicinal Chemistry Letters9 (1999) 1679-2684.
Chu-Biao Xue et al, “Synthesis and Antiplatelet Effects of An Isoxazole Series of Glycoprotein IIb/IIIa Antagonists”,Bioorganic&Medicinal Chemistry Letters, Letters 8 (1998) 3499-3504.
D. Chlarino et al., “Synthesis of New Isoxazole Aminoalcohols”,J. Heterocyclic Chem.25:(1) pp. 337-342 (1988) XP 002041517.
Steven P. Tanis and David B. Head, “Furans In Synthesis. The Preparation of (+)-Lactaral”,Tetrahedron Letters, 23:(52) pp. 5509-5512 (1982) XP002208603.
Pier Giovanni Beraldi et al., “Synthesis of 3-Substituted-7-alkoxy-5H-pyrazolo ′4, 3-dl-1,2,3-triazin-4(3H)-ones”Synthesis, pp. 1437-1440, (1994), XP002208604.
Thomas C. Bruice et al., “Rational design of substituted tripyrrole peptides that complex with DNA by both selective minor-groove binding and electrostatic interaction with the phosphate backbone”,Proc. Natl. Acad. Sci, 89: pp. 1700-1704 (Mar. 1992).
Baird et al., “Solid Phase Synthesis of Polyamides Containing Imidazole and Pyrrole Amino Acids,”J. Am. Chem. Soc., 118:6141-6146 (1996).
Arcamone et al., “Synthesis, DNA binding and antiviral activity of distamycin analogues containing different heterocyclic moieties,”Anti-Cancer Drug Design, 1:235-244 (1986).
El-Naggaar et al., “Synthesis of Some 2-Thenoyl-, 5-Bromo-2-thenoyl- and 5-Nitro-2 thenoylamino Acid Derivatives and their Antimicrobial Activity,”J. Indian Chem. Soc., LIX:783-786 (1982).
Sharma et al., “Design and Synthesis of Novel Thiazole-Containing Cross-Linked Polyamides Related to the Antiviral Antibiotic Distamycin,”J. Org. Chem, p. est: 5.3 (1999).
Plouvier et al., “DNA-sequence specific recognition by a thiazole analogue of netropsin: a comparative footprinting study,”Nucleic Acids Research, 19(21):5821-5829 (1991).
Kopka et al., “Defining GC-specificity in the minor groove: side-by-side binding of the di-imidazole lexitropsin to C-A-T-G-G-C-C-A-T-G,”Structure, 5(8):1033-1046 (1997).
Rao et al., “Molecular recognition between oligopeptides and nucleic acids: DNA sequence specificity and binding properties of thiazole-lexitropsins incorporating the concepts of base site acceptance and avoidance,”Anti-Cancer Drug Design, 5:3-20 (1990).
Zakrzewska et al., “Theoretical Study of the Sequence Selectivity of Isolexins, Isohelical DNA Groove Binding Ligands. Proposal for the GC Minor Groove Specific Compounds,”Journal of Biomolecular Structure&Dynamics, ISSN 0739-1102, 5(5):1043-1058 (1988).
Bailly et al., “Sequence-Specific DNA Minor Groove Binders. Design and Synthesis of Netropsin and Distamycin Analogues,”Bioconjugate Chemistry, 9(5):513-538 (1998).
Nielsen, “Sequence-Selective DNA Recognition by Synthetic Ligands,”Bioconjugate Chemistry, 2(1):1-12 (1991).
Vaquero et al., “Small ligands that neither bind to nor alter the structure of d(GA•TC)n sequences in DNA,”FEBS Letters, 420:156-160 (1997).
Matsumoto et al., “Synthesis of Sulfonamido Oligo-N-Methylpyrrole-Carboxamide Derivatives and Their Photochemical DNA Cleaving Activities,”Heterocycles, 33(1):135-138 (1992).
Berg, S.M. et al., “Pharmaceutical Salts”,Journal of Pharmaceutical Science, 66, 1-19 (1977).
Baird Eldon E.
Bürli Roland W.
Ge Yigong
Moser Heinz E.
Taylor Matthew J.
Genesoft Pharmaceuticals, Inc.
Riley Jezia
Townsend and Townsend / and Crew LLP
LandOfFree
Charged compounds comprising a nucleic acid binding moiety... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Charged compounds comprising a nucleic acid binding moiety..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Charged compounds comprising a nucleic acid binding moiety... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3530406